Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xL ratio

Cell Cycle

Volumn 11, Issue 10, 2012, Pages 1883-1887

  Goloudina, Anastasia R ^a   Mazur, Sharlyn J ^b   Appella, Ettore ^b   Garrido, Carmen ^a,c   Demidov, Oleg N ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Bax; Cisplatin; NF B; p53 negative; Phosphatase; Runx2; Wip1

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CASPASE 3; CASPASE 9; CHECKPOINT KINASE 1; CYCLIN B; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN WIP1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING; DNA DAMAGE; DOWN REGULATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; NEGATIVE FEEDBACK; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR CELL; WILD TYPE;

EID: 84861367028     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19901     Document Type: Review

References (44)

1. Basu A, Haldar S. The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4:1099-109; PMID:9872359; http://dx.doi.org/10.1093/molehr/4.12.1099.
2. Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ 2006; 13:1256-9; PMID:16710363; http://dx.doi.org/10.1038/sj.cdd.4401962.
3. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137:609-22; PMID:19450511; http://dx.doi.org/10.1016/j.cell.2009.04.050.
4. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004; 95:7-11; PMID:14720320; http://dx.doi.org/10.1111/j.1349-7006. 2004.tb03163.x.
5. Barak Y, Juven T, Haffner R, Oren M. Mdm2 expression is induced by wild-type p53 activity. EMBO J 1993; 12:461-8; PMID:8440237.
6. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997; 94:6048-53; PMID:9177166; http://dx.doi.org/10.1073/pnas.94.12.6048.
7. Rossi M, Demidov ON, Anderson CW, Appella E, Mazur SJ. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic Acids Res 2008; 36:7168-80; PMID:19015127; http://dx.doi.org/10.1093/nar/gkn888.
8. Ak P, Levine AJ. p53 and NFκB: different strategies for responding to stress lead to a functional antagonism. FASEB J 2010; 24:3643-52; PMID:20530750; http://dx.doi.org/10.1096/fj.10-160549.
9. Gudkov AV, Gurova KV, Komarova EA. Inflammation and p53: A Tale of Two Stresses. Genes Cancer 2011; 2:503-16; PMID:21779518; http://dx.doi.org/10.1177/ 1947601911409747.
10. Lain S, Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer 2003; 39:1053-60; PMID:12736103; http://dx.doi.org/10.1016/ S0959-8049(03)00063-7.
11. Martinez-Rivera M, Siddik ZH. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol 2012; 83:1049-62; PMID:22227014; http://dx.doi.org/10.1016/j.bcp.2011.12.026.
12. Giordana MT, Duó D, Gasverde S, Trevisan E, Boghi A, Morra I, et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro Oncol 2002; 4:115-22; PMID:11916503.
13. Lowe J, Cha H, Lee MO, Mazur SJ, Appella E, Fornace AJ Jr. Regulation of the Wip1 phosphatase and its effects on the stress response. Front Biosci 2012; 17:1480-98; PMID:22201816; http://dx.doi.org/10.2741/3999.
14. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008; 27:123-35; PMID:18265945; http://dx.doi.org/10.1007/s10555-008-9127-x.
15. Moon SH, Nguyen TA, Darlington Y, Lu X, Donehower LA. Dephosphorylation of γH2AX by WIP1: an important homeostatic regulatory event in DNA repair and cell cycle control. Cell Cycle 2010; 9:2092-6; PMID:20495376; http://dx.doi.org/10.4161/cc.9.11.11810.
16. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005; 19:1162-74; PMID:15870257; http://dx.doi.org/10.1101/gad.1291305.
17. Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 2006; 23:757-64; PMID:16949371; http://dx.doi.org/10.1016/j.molcel.2006.07.010.
18. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, et al. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19:6517-26; PMID:11101524; http://dx.doi.org/10.1093/emboj/19.23.6517.
19. Lu X, Nguyen TA, Donehower LA. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle 2005; 4:1060-4; PMID:15970689; http://dx.doi.org/10.4161/cc.4.8.1876.
20. McConnell JL, Wadzinski BE. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 2009; 75:1249-61; PMID:19299564; http://dx.doi.org/10.1124/mol.108.053140.
21. Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol 2011; 225:475-8; PMID:22025211; http://dx.doi.org/10.1002/path.2988.
22. Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10:477-84; PMID:12719725; http://dx.doi.org/10.1038/sj.cdd.4401194.
23. Bouchet BP, de Fromentel CC, Puisieux A, Galmarini CM. p53 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006; 58:190-207; PMID:16690321; http://dx.doi.org/10.1016/j.critrevonc.2005.10.005.
24. Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med 2011; 3:1; PMID:21209413; http://dx.doi.org/10.1126/scitranslmed.3001366.
25. Demidova AR, Aau MY, Zhuang L, Yu Q. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control. J Biol Chem 2009; 284:4132-9; PMID:19060337; http://dx.doi.org/10.1074/jbc.M808118200.
26. Greenow KR, Clarke AR, Jones RH. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 2009; 28:1443-53; PMID:19169280; http://dx.doi.org/10. 1038/onc.2008.482.
27. Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV, et al. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci USA 2012; 109:68-75; PMID:22065775; http://dx.doi.org/10.1073/pnas. 1107017108.
28. Jurvansuu J, Fragkos M, Ingemarsdotter C, Beard P. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling. J Mol Biol 2007; 372:397-406; PMID:17663993; http://dx.doi.org/10.1016/j.jmb.2007.06.077.
29. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001; 20:7453-63; PMID:11709716; http://dx.doi.org/10.1038/sj. onc.1204942.
30. Goloudina A, Yamaguchi H, Chervyakova DB, Appella E, Fornace AJ Jr, Bulavin DV. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle 2003; 2:473-8; PMID:12963847; http://dx.doi.org/10.4161/cc.2.5.482.
31. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-805; PMID:8183579.
32. Eliseev RA, Dong YF, Sampson E, Zuscik MJ, Schwarz EM, O'Keefe RJ, et al. Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 2008; 27:3605-14; PMID:18223689; http://dx.doi.org/10.1038/sj.onc.1211020.
33. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 2008; 99:33-76; PMID:18037406; http://dx.doi.org/10.1016/S0065-230X(07)99002-8.
34. Ge C, Xiao G, Jiang D, Yang Q, Hatch NE, Roca H, et al. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J Biol Chem 2009; 284:32533-43; PMID:19801668; http://dx.doi.org/10.1074/jbc.M109.040980.
35. Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem 2006; 281:7118-28; PMID:16407259; http://dx.doi.org/10.1074/jbc.M508162200.
36. Rajgopal A, Young DW, Mujeeb KA, Stein JL, Lian JB, van Wijnen AJ, et al. Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells. J Cell Biochem 2007; 100:1509-17; PMID:17171635; http://dx.doi.org/10.1002/jcb.21137.
37. Wee HJ, Huang G, Shigesada K, Ito Y. Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms. EMBO Rep 2002; 3:967-74; PMID:12231506; http://dx.doi.org/10.1093/embo-reports/kvf193.
38. Cianfrocca R, Muscolini M, Marzano V, Annibaldi A, Marinari B, Levrero M, et al. RelA/NFkappaB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ 2008; 15:354-63; PMID:18034190; http://dx.doi.org/10.1038/sj.cdd.4402264.
39. +lymphocytes. J Immunol 2000; 165:1743-54; PMID:10925251.
40. L gene promoters. Proc Natl Acad Sci USA 2004; 101:6098-103; PMID:15079071; http://dx.doi.org/10.1073/pnas.0308688101.
41. Chew J, Biswas S, Shreeram S, Humaidi M, Wong ET, Dhillion MK, et al. WIP1 phosphatase is a negative regulator of NFkappaB signalling. Nat Cell Biol 2009; 11:659-66; PMID:19377466; http://dx.doi.org/10.1038/ncb1873.
42. Lowe JM, Cha H, Yang Q, Fornace AJ Jr. Nuclear factor kappaB (NFkappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase. J Biol Chem 2010; 285:5249-57; PMID:20007970; http://dx.doi.org/10.1074/jbc. M109.034579.
43. Salminen A, Kaarniranta K. Control of p53 and NFêB signaling by WIP1 and MIF: role in cellular senescence and organismal aging. Cell Signal 2011; 23:747-52; PMID:20940041; http://dx.doi.org/10.1016/j.cellsig.2010.10.012.
44. Webster GA, Perkins ND. Transcriptional cross talk between NFkappaB and p53. Mol Cell Biol 1999; 19:3485-95; PMID:10207072.